Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to
elevated pressures within the pulmonary arteries. Five main groups of pulmonary …

There is a need for clinical trial end-points to better assess how patients feel and function, so
that interventions can be developed which alleviate symptoms and improve quality of life …

Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It
affects the lungs in over 90% of patients yet extra-pulmonary and multi-organ involvement is …

Introduction Advanced pulmonary sarcoidosis refers to phenotypes of pulmonary
sarcoidosis that often lead to significant loss of lung function, respiratory failure, or death …

Rationale The six-minute walk test (6MWT) is a practical and simple field-based test to
assess physical capacity. Several reference equations for six-minute walking distance …

The efficacy of treating sarcoidosis‐associated pulmonary hypertension (SAPH) with
pulmonary vasodilator therapy is unclear. The INCREASE trial showed improvement in 6 …

Pulmonary sarcoidosis is the most common interstitial lung disease (ILD), especially in
middle-aged patients. 1, 2 Because of its heterogeneous onset and manifestations, the initial …

Pulmonary vascular involvement is a common complication in sarcoidosis, particularly in
advanced disease. 1 The mechanisms leading to the development of pulmonary …

Although sarcoidosis is generally regarded as a benign condition, approximately 20–30% of
patients will develop a chronic and progressive disease. Advanced pulmonary fibrotic …

Fibrotic pulmonary sarcoidosis represents a distinct and relatively uncommon manifestation
within the spectrum of sarcoidosis and has substantial morbidity and mortality. Due to the …